Skip to main content
SpringerLink
Log in

Delandistrogene Moxeparvovec: First Approval

  • AdisInsight Report
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Delandistrogene moxeparvovec (delandistrogene moxeparvovec-rokl; ELEVIDYS®) is an adeno-associated virus (AAV) vector-based gene therapy designed to deliver a gene encoding a micro-dystrophin protein [i.e. a shortened (138 kDa) version of the dystrophin protein expressed in normal muscle cells (427 kDa)] to all muscles involved in the pathology of Duchenne muscular dystrophy (DMD). Developed by Sarepta Therapeutics, it is the first gene therapy to be approved (in June 2023 under the Accelerated Approval pathway) for the treatment of DMD in the USA, where it is indicated for ambulatory paediatric patients aged 4 through 5 years with DMD and a confirmed mutation in the dystrophin (DMD) gene. The recommended dose of delandistrogene moxeparvovec is 1.33 × 1014 vector genomes per kg of body weight or 10 mL/kg body weight, administered as a single intravenous infusion. Delandistrogene moxeparvovec is undergoing clinical development in several countries/regions, including the EU and Japan. This article summarizes the milestones in the development of delandistrogene moxeparvovec leading to this first approval in the USA for the treatment of ambulatory paediatric patients aged 4 through 5 years with DMD and a confirmed mutation in the DMD gene.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Duan D, Goemans N, Takeda S, et al. Duchenne muscular dystrophy. Nat Rev Dis Primers. 2021;7(1):13.

    Article  PubMed  Google Scholar 

  2. Chang M, Cai Y, Gao Z, et al. Duchenne muscular dystrophy: pathogenesis and promising therapies. J Neurol. 2023;270(8):3733–49.

    Article  CAS  PubMed  Google Scholar 

  3. Birnkrant DJ, Bello L, Butterfield RJ, et al. Cardiorespiratory management of Duchenne muscular dystrophy: emerging therapies, neuromuscular genetics, and new clinical challenges. Lancet Respir Med. 2022;10(4):403–20.

    Article  PubMed  Google Scholar 

  4. Asher DR, Thapa K, Dharia SD, et al. Clinical development on the frontier: gene therapy for Duchenne muscular dystrophy. Expert Opin Biol Ther. 2020;20(3):263–74.

    Article  CAS  PubMed  Google Scholar 

  5. Schneider AE, Aartsma-Rus A. Developments in reading frame restoring therapy approaches for Duchenne muscular dystrophy. Expert Opin Biol Ther. 2021;21(3):343–59.

    Article  CAS  PubMed  Google Scholar 

  6. Muntoni F, Domingos J, Manzur AY, et al. Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy. PLoS One. 2019;14(9): e0221097.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Mendell JR, Sahenk Z, Lehman K, et al. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol. 2020;77(9):1122–31.

    Article  PubMed  Google Scholar 

  8. Sarepta Therapeutics Inc. ELEVIDYS (delandistrogene moxeparvovec-rokl) suspension, for intravenous infusion: US prescribing information; 2023. https://www.fda.gov/. Accessed 23 Jun 2023.

  9. Sarepta Therapeutics. Sarepta Therapeutics announces FDA approval of ELEVIDYS, the first gene therapy to treat Duchenne muscular dystrophy [media release]; 22 Jun 2023. https://www.sarepta.com/.

  10. US Food and Drug Administration. FDA approves first gene therapy for treatment of certain patients with Duchenne muscular dystrophy [media release]; 22 Jun 2023. https://www.fda.gov/.

  11. Roche. Roche enters licensing agreement with Sarepta Therapeutics to improve the lives of patients living with Duchenne muscular dystrophy [media release]; 23 Dec 2019. http://www.roche.com.

  12. Sarepta Therapeutics. Sarepta Therapeutics and Selecta Biosciences enter into research license and option agreement for Selectas ImmTOR immune tolerance platform in neuromuscular diseases [media release]; 18 Jun 2020. http://www.sarepta.com.

  13. Chugai Pharmaceutical. Chugai in-licenses gene therapy delandistrogene moxeparvovec (SRP-9001) for Duchenne muscular dystrophy [media release]; 16 Dec 2021. https://www.chugai-pharm.co.jp/.

  14. Selecta Biosciences. Selecta Biosciences announces partnership advancements and clinical trial updates [media release]; 13 Jun 2022. http://www.selectabio.com.

  15. Mendell J, Shieh P, McDonald C, et al. Expression of SRP-9001 dystrophin and stabilization of motor function up to 2 years post-treatment with delandistrogene moxeparvovec gene therapy in individuals with Duchenne muscular dystrophy. Front Cell Dev Biol. 2023;11: 1167762.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Proud C, Zaidman C, McDonald C, et al. One-year data from ENDEAVOR, a phase 1b trial of delandistrogene moxeparvovec in patients with DMD [abstract no. 107 plus oral]. In: Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. 2023.

  17. Malhotra J, Lewis S, Zhang X, et al. Analysis of vector shedding following treatment with delandistrogene moxeparvovec, an investigational rAAVrh74-based gene therapy for DMD [abstract no. LSVP.35 plus poster]. Neuromuscul Disord. 2022;32(Suppl 1):47.

    Google Scholar 

  18. Klimchak AC, Sedita LE, Rodino-Klapac LR, et al. Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States. J Mark Access Health Policy. 2023;11:1–14.

    Google Scholar 

  19. Sarepta Therapeutics. Sarepta Therapeutics reports sustained functional improvement two years after treatment with SRP-9001, its investigational micro-dystrophin gene therapy for Duchenne muscular dystrophy [media release]; 28 Sep 2020. http://www.sarepta.com.

  20. Mendell J, Sahenk Z, Lehman K, et al. Phase 1/2a trial of delandistrogene moxeparvovec in patients with DMD: 4-year update [abstract no. 354 plus presentation]. Mol Ther. 2023;31(4 Suppl 1):190–1.

    Google Scholar 

  21. Zaidman C, Proud C, McDonald C, et al. One-year data from ENDEAVOR, a phase 1b trial of delandistrogene moxeparvovec in boys with DMD [abstract no. P.129 plus poster]. Neuromuscul Disord. 2022;32(Suppl 1):S101.

  22. Goedeker NL, Aqul A, Butterfield RJ, et al. Management of patients following investigational delandistrogene moxeparvovec gene therapy for Duchenne muscular dystrophy: Delphi panel consensus considerations based on clinical trial experience [abstract no. 132 plus poster]. Mol Ther. 2023;31(4S1):71.

Download references

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Sheridan M. Hoy

Authors
  1. Sheridan M. Hoy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sheridan M. Hoy.

Ethics declarations

Funding

The preparation of this review was not supported by any external funding.

Authorship and Conflict of Interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sheridan M. Hoy is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PPTX 504 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hoy, S.M. Delandistrogene Moxeparvovec: First Approval. Drugs 83, 1323–1329 (2023). https://doi.org/10.1007/s40265-023-01929-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40265-023-01929-x

Search

Navigation